Regeneron R2176-3-AMD-1417 CAPELLA
Posted by: Georgia Retina in
Research Title: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity…
Read More
Regeneron R910-3-AMD-1517 ONYX
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Realted Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI). Start…
Read More Regeneron R910-3-DME-1518 RUBY
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving…
Read More Regeneron VGFTe-OD-1411 PANORAMA
Posted by: Georgia Retina in
Research Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to…
Read More RIDE FVF4168g
Posted by: Georgia Retina in
Research Title: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RIDE) Sponsor: Genentech Principal Investigator: Michael Jacobson, M.D. Description: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type…
Read More RISE FVF4170g
Posted by: Georgia Retina in
Research Title: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE) Sponsor: Genentech Principal Investigator: Michael Jacobson, M.D. Description: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type…
Read More Roche BP29647 AVENUE
Posted by: Georgia Retina in
Research Title: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RG7716 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Sponsor: Hoffmanm-La Roche Principal Investigator: Jay Stallman, M.D., F.A.C.S. Description: This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy…
Read More KalVista KVD011-201
Posted by: Georgia Retina in
Research Title: A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment. Sponsor: KalVista Pharmaceticals, Ltd. Principal Investigator: Robert Stoltz, M.D., Ph.D Description: The purpose of this study is to evaluate…
Read More LFG316A2203
Posted by: Georgia Retina in
Research Title: A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration Sponsor: Novartis Principal Investigator: Mark J. Rivellese, M.D. Description: This study is designed to test the efficacy of six successive monthly doses of intravitreal (IVT) LFG316 on the growth of geographic atrophy (GA) lesions. The study will also…
Read More OPH1004
Posted by: Georgia Retina in
Research Title: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration. Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: Subjects will be randomized…
Read More 
